



## Vikas Lifecare Ltd.

(Formerly known as Vikas Multicorp Ltd.)

CIN : L25111DL1995PLC073719

Regd. Off : G-1, 34/1,  
East Punjabi Bagh, New Delhi-110 026, INDIA

January 10, 2022

Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra-Kurla Complex,  
Bandra (E), Mumbai 400 051  
**NSE Symbol: VIKASLIFE**

Deptt of Corporate Services  
BSE Limited  
Phirozee Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai 400 001  
**Scrip Code: 542655**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on January 10, 2022**

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e January 10, 2022 at the Registered Office of the Company situated at G-1 34/1, East Punjabi Bagh, New Delhi - 110026, subject to members approval wherever necessary, *inter-alia*, considered and approved:

- i. the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021 in terms of Regulation 33 of Listing Regulations. Copy of financial results along with the Limited Review report thereon issued by the Statutory Auditor is enclosed;
- ii. making of the first and final call of Rs. 1.70/- (comprising Re. 0.60/- towards face value and Re. 1.10/- towards securities premium) per partly paid-up equity share ("the Call"), on 17,69,32,132 outstanding partly paid-up equity shares of face value Re. 1/- each, issued by the Company on a rights basis, pursuant to its Letter of Offer dated October 26, 2021;

Details of the Call are as below:

**Call Record date:**

The Board of Directors of the Company has fixed **Friday, January 14, 2022** as the Record Date for the purpose of determining the holders of partly paid-up equity shares to whom the Call notice will be dispatched for payment of the Call.

**Call payment period:**

The Call payment period will open on **Thursday, January 20, 2022** and close on **Thursday, February 3, 2022** (both days inclusive).

Further details in relation to the Call, will be included in the Call notice that will be dispatched separately in due course.

- iii. venturing into new edge businesses, make investment up to Rs. 200 crores in various opportunities of strategic alliances, business association, joint-ventures, and alike business propositions;

*Continue...*



-//2//-

- iv. in order to augment the long-term resources and fund organic/inorganic growth opportunities in the area of the company's operations and adjacencies, raising of funds by way of further issue of securities including equity shares, other convertible securities, warrants and bonds (whether convertible or nonconvertible) or any combination thereof through QIP, FCCB, ADRs, GDRs and/or FPO or through any other permissible mode or any combination thereof, for an aggregate amount not exceeding Rs. 200 Crore [Rupees Two Hundred Crore], subject to applicable laws and necessary shareholder / regulatory approvals, as applicable, with a view to capitalize on available growth opportunities and continues to evaluate avenues for organic and inorganic growth.

Further, for the purpose of giving effect to the above, the Board of Directors has also constituted the 'Fund Raising Committee' and authorised such committee to decide, inter alia, the terms and conditions of the proposed fund-raising program and for allotment of equity shares and/or other convertible securities, pursuant to the proposed issue;

- v. increase in Authorized Share Capital of the Company from existing Rs. 1,25,00,00,000/- (Rupees One hundred and Twenty-Five Crores) to Rs. 150,00,00,000/- (Rupees One hundred and Fifty Crores) by creation of new equity shares;
- vi. necessary alteration in relevant clauses of the Memorandum and Articles of Association of the Company;
- vii. to seek requisite members approval for abovesaid items, wherever necessary, by way of passing resolutions through Postal Ballot, process being initiated separately.

The meeting was duly commenced at 5:25 PM and concluded at 8:45 PM.

You are requested to take the information on record and oblige.

Thanking you,

Yours Faithfully,

for **Vikas Lifecare Limited**  
**MONIKA** Digitally signed  
by **MONIKA**  
**SONI** SONI  
**Monika Soni**  
**Company Secretary**

**LIMITED REVIEW REPORT ON REVIEW OF STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS RESULTS OF VIKAS LIFECARE LIMITED (FORMERLY VIKAS MULTICORP LIMITED) FOR THE PERIOD ENDED 31<sup>th</sup> DECEMBER, 2021**

**TO**

**THE BOARD OF DIRECTORS**

**VIKAS LIFECARE LIMITED (Formerly Known as Vikas Multicorp Limited)**

We have reviewed the accompanying statement of Standalone unaudited financial results of **M/s VIKAS LIFECARE LIMITED (Formerly Known as Vikas Multicorp Limited)** ('the Company') for the quarter and **Nine Months** ended 31<sup>th</sup> December, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, including relevant circulars issued by SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Standalone Financial Result in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Standalone Statement of unaudited financial results, prepared in accordance with applicable principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34)



906, Vikram Tower, 16 Rajendra Place  
New Delhi - 110008

[www.rsphindia.com](http://www.rsphindia.com)

+91 11 41538933, 25715850

[tarun@rsphindia.com](mailto:tarun@rsphindia.com), [catarunbatra@gmail.com](mailto:catarunbatra@gmail.com)



prescribed under section 133 of the Companies Act 2013 read with rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information in terms of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For RSPH & Associates**  
**Chartered Accountants**  
**Firm Registration No: 003013N**



A handwritten signature in blue ink, appearing to read 'Tarun Kumar Batra', written over a horizontal line.

**CA Tarun Kumar Batra**  
**Partner**  
**M No.: 094318**  
**UDIN: 22094318AAAAAP4392**  
**Date: -10/01/2022**  
**Place: Delhi**

**VIKAS LIFECARE LIMITED**  
**(FORMERLY KNOWN AS VIKAS MULTICORP LIMITED)**

CIN - L25111DL1995PLC073719

REGD OFF: G-1,VIKAS HOUSE, 34/1, EAST PUNJABI BAGH, NEW DELHI -110026, PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

**UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2021**


Sr. No.		Three Months Ended			Nine Months Ended		Figures in Laacs
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	Year Ended 31-Mar-21
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue from Operations</b>						
a.	Revenue from Operations	10,674.10	6,748.93	942.95	19,833.44	4,493.90	7,499.45
2	<b>Other Income</b>	737.01	427.66	375.68	1,287.69	582.02	917.06
3	<b>Total Income (1+2)</b>	<b>11,411.11</b>	<b>7,176.59</b>	<b>1,318.63</b>	<b>21,121.13</b>	<b>5,075.92</b>	<b>8,416.51</b>
4	<b>EXPENSES :</b>						
a.	Cost of Materials Consumed	570.53	943.23	626.19	1,837.63	3,890.15	2,437.83
b.	Purchases of Stock-in-Trade	10,348.53	5,976.09		18,384.08	-	3,335.53
c.	Change in inventory of finished goods, work in progress and stock in trade	(429.73)	(354.60)	294.36	(972.71)	329.69	602.56
d.	Employee Benefits Expense	39.65	39.17	17.54	98.06	46.36	65.63
e.	Finance Costs	25.30	12.25	101.34	170.45	380.56	535.39
f.	Depreciation and Amortisation Expense	11.57	36.29	14.18	69.29	43.45	68.43
g.	Other Expenses	457.53	217.83	254.75	795.73	323.10	280.70
	<b>Total Expenses</b>	<b>11,023.38</b>	<b>6,870.26</b>	<b>1,308.36</b>	<b>20,382.53</b>	<b>5,013.31</b>	<b>7,326.07</b>
5	<b>Profit Before Exceptional Items and Tax (3-4)</b>	<b>387.73</b>	<b>306.33</b>	<b>10.27</b>	<b>738.60</b>	<b>62.61</b>	<b>1,090.44</b>
6	Exceptional Items	-	-	-	-	-	(1,240.42)
7	<b>Profit/(Loss) Before Tax (5-6)</b>	<b>387.73</b>	<b>306.33</b>	<b>10.27</b>	<b>738.60</b>	<b>62.61</b>	<b>(149.98)</b>
8	<b>Tax Expense/(Benefits):</b>						
i.	Current Tax	36.38	48.43	3.65	96.02	16.82	137.46
ii.	Deferred Tax	63.24	1.57		64.81	-	29.15
iii.	Previous Year Income Tax	-	-		-	-	33.56
	<b>Total Tax Expense (i+ii+iii)</b>	<b>99.62</b>	<b>50.00</b>	<b>3.65</b>	<b>160.83</b>	<b>16.82</b>	<b>200.17</b>
9	<b>Net Profit/(Loss) from continuing operations (7-8)</b>	<b>288.11</b>	<b>256.33</b>	<b>6.62</b>	<b>577.77</b>	<b>45.79</b>	<b>(350.15)</b>
10	Profit/(loss) from discontinued operations	-	-	-	-	-	-
11	Tax expenses of discontinued operations	-	-	-	-	-	-
12	<b>Profit/(loss) from Discontinued operations (after tax) (10-11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Profit/(loss) for the period (9+12)</b>	<b>288.11</b>	<b>256.33</b>	<b>6.62</b>	<b>577.77</b>	<b>45.79</b>	<b>(350.15)</b>
	<b>Other Comprehensive Income :</b>						
A.)	(i) Items that will not be reclassified to Profit and Loss	373.47	597.79	(1,344.01)	1,081.90	(2,119.20)	1,661.42
	(ii) income tax relating to items that will not be reclassified to profit or loss	(0.74)	(1.13)	(81.26)	(1.93)		4.64
B)	(i) items that will be reclassified to profit and loss account	-	-	-			-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-		220.40	(1.21)
14	<b>Total Other Comprehensive Income</b>	<b>372.73</b>	<b>596.66</b>	<b>(1,426.38)</b>	<b>1,079.97</b>	<b>(1,898.80)</b>	<b>1,664.85</b>
15	<b>Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13+14)</b>	<b>660.84</b>	<b>852.99</b>	<b>(1,419.76)</b>	<b>1,657.74</b>	<b>(1,853.01)</b>	<b>1,314.70</b>
16	Paid up Equity Share Capital (Face Value Rs.1 each)	9,996.67	9,996.67	6,634.95	9,996.67	6,634.95	6,634.95
17	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	4,640.39	4,352.28	2,633.64	4,640.39	2,633.64	1,806.75
18	<b>Earning per Equity Share:</b>						
	Equity shares of par value Rs 1 each						
	(EPS for three and six months ended periods are not annualised)						
	Basic	0.03	0.03	(0.21)	0.06	(0.28)	(0.05)
	Diluted	0.03	0.03	(0.21)	0.06	(0.28)	(0.05)



**\*Financial Results for the Quarter and Nine Months ended 31st December, 2021****Notes:**

1	The standalone financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.										
2	The above Quarterly and Nine Months results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held in January 10, 2021. The Statutory auditors have carried out a limited review of the results for the quarter and Nine Month ended December 31, 2021.										
3	The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share (not annualized) in accordance with the Ind AS.										
4	Prior period Expenses/Income pertains to previous year, accordingly previous year figures has been restated. Previous year/period figures have been regrouped/reclassified/rearranged, wherever necessary.										
5	In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".										
6	The Company has received proceeds of recently concluded Right Issue, wherein partly paid 17,69,32,132 Equity Shares of Re. 1/- each (Re. 0.40/- partly paid up) allotted on Rights basis to the eligible shareholders, in its Bank Account. The Company is in the process of deploying these fund as per the objects of the Right Issue. These partly paid shares are listed with BSE (Scrip Code: 890160) and NSE (Symbol: VLIFEPP) both, trading commenced on Monday, December 13, 2021.										
7	The results of the Company are also available for investors at <a href="http://www.vikaslifecarelimited.com">www.vikaslifecarelimited.com</a> , <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a>										
8	The Previous year figures has been audited Reviewed by the erstwhile Statutory auditors.										
9	During the quarter under review the company has made provision of Rs 40,08,000 on investment. The company has filed case against Astitva Capital Market Private Limited which has sold 40,00,000 Equity shares of M/s Vikas Ecotech Limited held by the company without any authorisation from the company.										
10	During the quarter under review, the company has reversed Interest Income of Rs 51,34,816.70 under head other expenses, which was booked during the financial year 2020-21 on account of settlement of the litigation filed by the company against the customer before NCLT, Chandigarh.										
11	Equity Investment in associate company i.e Advik Laboratories Limited taken at cost as per Ind AS-28. Company holds 22.04 % shares in its associates company.										
12	<table border="1"><thead><tr><th colspan="2">INVESTOR COMPLAINTS</th></tr></thead><tbody><tr><td>Pending at the beginning of the quarter</td><td>0</td></tr><tr><td>Received during the quarter</td><td>1</td></tr><tr><td>Disposed off during the quarter</td><td>1</td></tr><tr><td>Remaining unresolved at the end of the quarter</td><td>0</td></tr></tbody></table>	INVESTOR COMPLAINTS		Pending at the beginning of the quarter	0	Received during the quarter	1	Disposed off during the quarter	1	Remaining unresolved at the end of the quarter	0
INVESTOR COMPLAINTS											
Pending at the beginning of the quarter	0										
Received during the quarter	1										
Disposed off during the quarter	1										
Remaining unresolved at the end of the quarter	0										

for Vikas LifeCare Limited

Vivek Garg  
Director

DIN: 00255443

Place: New Delhi  
Date: 10.01.2022

**Limited Review Report on consolidated unaudited quarterly and Nine Months financial results of the Company for the quarter and Nine Months ended 31<sup>st</sup> December, 2021 (Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)**

TO

**THE BOARD OF DIRECTORS**

**Vikas Lifecare Limited**

**(Formerly Known as Vikas Multicorp Limited )**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Vikas Lifecare Limited (Formerly Known as Vikas Multicorp Limited) ("the Parent") and its Associate (the Parent and its Associate together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / (loss) of its associate for the quarter ended 31<sup>st</sup> December 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated financial statements have been prepared wherein the consolidated figures for the corresponding quarter ending 31<sup>st</sup> December 2020, Nine months ending 31<sup>st</sup> December 2020 and year ending 31<sup>st</sup> March 2021 are taken from the standalone financial statements/ financial results as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



906, Vikram Tower, 16 Rajendra Place  
New Delhi - 110008

[www.rsphindia.com](http://www.rsphindia.com)  
+91 11 41538933, 25715850

[tarun@rsphindia.com](mailto:tarun@rsphindia.com), [catarunbatra@gmail.com](mailto:catarunbatra@gmail.com)



3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Following Entities: -

Name of the Company	Relationship
M/s Advik Laboratories Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the associates reviewed by the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Statement includes the Parents share of Net Loss after Tax of Rs. 6.06 Lacs and Total Comprehensive Income of Rs. 0.02 Lacs for the quarter ending 31<sup>st</sup> December 2021 and the Parents share of Net Loss after Tax of Rs. 12.48 Lacs and Total Comprehensive Income of Rs. 0.07 Lacs for the nine months ending 31<sup>st</sup> December 2021 respectively as considered in the statement, in respect of an associate whose consolidated financial information have not been reviewed by us. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us





by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

**For RSPH & Associates**  
**Chartered Accountants**  
**Firm Registration No: 003013N**



**CA Tarun Kumar Batra**  
**Partner**  
**M No.: 094318**  
**UDIN: 22094318AAAAAQ8438**  
**Date: -10/01/2022**  
**Place: Delhi**

**VIKAS LIFECARE LIMITED**  
**(FORMERLY KNOWN AS VIKAS MULTICORP LIMITED)**

CIN - L25111DL1995PLC073719

REGD OFF: G-1,VIKAS HOUSE, 34/1. EAST PUNJABI BAGH, NEW DELHI -110026, PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

**UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021**

Particulars		Figures in Lacs					
		Three Months Ended			Nine Months Ended		Year Ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
Sr. No.		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue from Operations</b>						
a.	Revenue from Operations	10,674.10	6,748.93	942.95	19,833.44	4,493.90	7,499.45
2	<b>Other Income</b>	737.01	427.66	375.68	1,287.69	582.02	917.06
3	<b>Total Income (1+2)</b>	<b>11,411.11</b>	<b>7,176.59</b>	<b>1,318.63</b>	<b>21,121.13</b>	<b>5,075.92</b>	<b>8,416.51</b>
4	<b>EXPENSES :</b>						
a.	Cost of Materials Consumed	570.53	943.23	626.19	1,837.63	3,890.15	2,437.83
b.	Purchases of Stock-in-Trade	10,348.53	5,976.09		18,384.08	-	3,335.53
c.	Change in inventory of finished goods, work in progress and stock in trade	(429.73)	(354.60)	294.36	(972.71)	329.69	602.56
d.	Employee Benefits Expense	39.65	39.17	17.54	98.06	46.36	65.63
e.	Finance Costs	25.30	12.25	101.34	170.45	380.56	535.39
f.	Depreciation and Amortisation Expense	11.57	36.29	14.18	69.29	43.45	68.43
g.	Other Expenses	457.53	217.83	254.75	795.73	323.10	280.70
	<b>Total Expenses</b>	<b>11,023.38</b>	<b>6,870.26</b>	<b>1,308.36</b>	<b>20,382.53</b>	<b>5,013.31</b>	<b>7,326.07</b>
5	<b>Profit Before Exceptional Items and Tax (3-4)</b>	<b>387.73</b>	<b>306.33</b>	<b>10.27</b>	<b>738.60</b>	<b>62.61</b>	<b>1,090.44</b>
6	Exceptional Items	-	-	-	-	-	(1,240.42)
7	Share of Profit / (loss) of associates	(6.06)	(6.42)	-	(12.48)	-	-
8	<b>Profit/ (Loss) Before Tax (5+6+7)</b>	<b>381.67</b>	<b>299.91</b>	<b>10.27</b>	<b>726.12</b>	<b>62.61</b>	<b>(149.98)</b>
9	<b>Tax Expense/(Benefits):</b>						
i.	Current Tax	36.38	48.43	3.65	96.02	16.82	137.46
ii.	Deferred Tax	63.24	1.57		64.81	-	29.15
iii.	Previous Year Income Tax	-	-	-	-	-	33.56
	<b>Total Tax Expense (i+ii+iii)</b>	<b>99.62</b>	<b>50.00</b>	<b>3.65</b>	<b>160.83</b>	<b>16.82</b>	<b>200.17</b>
10	<b>Net Profit/(Loss) from continuing operations (8-9)</b>	<b>282.05</b>	<b>249.91</b>	<b>6.62</b>	<b>565.29</b>	<b>45.79</b>	<b>(350.15)</b>
11	Profit/(loss) from discontinued operations	-	-	-	-	-	-
12	Tax expenses of discontinued operations	-	-	-	-	-	-
13	Profit/(loss) from Discontinued operations (after tax) (11-12)	-	-	-	-	-	-
14	<b>Profit/(loss) for the period (10+13)</b>	<b>282.05</b>	<b>249.91</b>	<b>6.62</b>	<b>565.29</b>	<b>45.79</b>	<b>(350.15)</b>
	<b>Other Comprehensive Income :</b>						
A.)	(i) Items that will not be reclassified to Profit and Loss	373.47	597.79	(1,344.01)	1,081.90	(2,119.20)	1,661.42
	(ii) income tax relating to items that will not be reclassified to profit or loss	(0.74)	(1.13)	(81.26)	(1.93)		4.64
B)	(i) items that will be reclassified to profit and loss account	-	-	-			-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-		220.40	(1.21)
	Share of Other Comprehensive Income of associates	0.02	0.05	-	0.07	-	-
15	<b>Total Other Comprehensive Income</b>	<b>372.75</b>	<b>596.71</b>	<b>(1,425.27)</b>	<b>1,080.04</b>	<b>(1,898.80)</b>	<b>1,664.85</b>
16	<b>Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (14+15)</b>	<b>654.80</b>	<b>846.62</b>	<b>(1,418.65)</b>	<b>1,645.33</b>	<b>(1,853.01)</b>	<b>1,314.70</b>
17	Paid up Equity Share Capital (Face Value Rs.1 each)	9,996.67	9,996.67	6,634.95	9,996.67	6,634.94	6,634.95
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	4,668.17	4,386.12	2,633.64	4,668.17	2,633.64	1,806.75
19	<b>Earning per Equity Share:</b>						
	Equity shares of par value Rs 1 each						
	(EPS for three and six months ended periods are not annualised)						
	Basic	0.03	0.03	(0.21)	0.06	(0.28)	(0.05)
	Diluted	0.03	0.03	(0.21)	0.06	(0.28)	(0.05)


\*Financial Results for the Quarter and Nine Months ended 31st December, 2021



## Notes:

1	The consolidated financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.	
2	The above Quarterly and Nine Months results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting in their held in January 10, 2021. The Statutory auditors have carried out a limited review of the results for the quarter and Nine Month ended December 31, 2021.	
3	The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share (not annualized) in accordance with the Ind AS.	
4	Prior period Expenses/Income pertains to previous year, accordingly previous year figures has been restated. Previous year/period figures have been regrouped/reclassified/rearranged, wherever necessary.	
5	In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".	
6	The Company has received proceeds of recently concluded Right Issue, wherein partly paid 17,69,32,132 Equity Shares of Re. 1/- each (Re. 0.40/- partly paid up) allotted on Rights basis to the eligible shareholders, in its Bank Account. The Company is in the process of deploying these fund as per the objects of the Right Issue. These partly paid shares are listed with BSE (Scrip Code: 890160) and NSE (Symbol: VLIFEPP) both, trading commenced on Monday, December 13, 2021.	
7	The results of the Company are also available for investors at <a href="http://www.vikalifecarelimited.com">www.vikalifecarelimited.com</a> , <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a>	
8	The Previous year figures has been audited Reviewed by the erstwhile Statutory auditors.	
9	During the quarter under review the company has made provision of Rs 40,08,000 on investment,as the company has filed case against Astitva Capital Market Private Limited which has sold 40,00,000 shares of M/s Vikas Ecotech Limited held by the company without any authorisation from the company.	
10	During the quarter under review, the company has reversed Interest Income of Rs 51,34,816.70 under head other expenses,which was booked during the financial year 2020-21 on account of settlement of the litigation filed by the company against the customer before NCLT,Chandigarh.	
11	As at 31st December 2021, the company held 22.04% interest in M/s Advik Laboratories Limited, accounted for using Equity Method.	
12	The consolidated financial statements have been prepared as company has acquired 22.04% interest of M/s Advik Laboratories Limited on 12 July 2021 and the consolidated figures for the corresponding quarter ending 31st December 2020 , Nine Month ending 31st December 2020 and Year ending 31st March 2021 disclosed in the above results taken from the standlone financial results approved by the board of directors.	
13	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	1
	Disposed off during the quarter	1
	Remaining unresolved at the end of the quarter	0

for Vikas LifeCare Limited



Vivek Garg

Director

DIN: 00255443

Place: New Delhi

Date: 10.01.2022